Eight More Years: US Supreme Court Sinks Sandoz’ Hopes On Enbrel
Erelzi Biosimilar Etanercept Is Now Barred Until 2029 In The US
Executive Summary
Sandoz’ arguments urging the US Supreme Court to review patent litigation around Amgen’s Enbrel have fallen on deaf ears, blocking a route to market for biosimilar etanercept until 2029 in the US.
You may also be interested in...
What Aspects Will Give Humira Biosimilars The Edge In 2023?
With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.
Reed Sets Out Priorities For US Biosimilars Forum
In an exclusive interview with Generics Bulletin, the Biosimilars Forum’s executive director Julie Reed sets out the group’s priorities and explains how its diverse membership is helping to position it as a leading voice for the US biosimilars industry.
Induced Infringement And Price Fixing Among Legal Headlines In 2021
In 2021, courts across the US and beyond continued to weigh key patent litigation fights, alongside the thorny issue of induced infringement via label carve outs and controversial charges for generic price fixing.